These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 20053161)

  • 21. Label-free screening assays: a strategy for finding better drug candidates.
    Lunn CA
    Future Med Chem; 2010 Nov; 2(11):1703-16. PubMed ID: 21428840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A fluorescent cell-based assay for cytochrome P-450 isozyme 1A2 induction and inhibition.
    Kelly JH; Sussman NL
    J Biomol Screen; 2000 Aug; 5(4):249-54. PubMed ID: 10992045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition and induction of human cytochrome P450 enzymes: current status.
    Pelkonen O; Turpeinen M; Hakkola J; Honkakoski P; Hukkanen J; Raunio H
    Arch Toxicol; 2008 Oct; 82(10):667-715. PubMed ID: 18618097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatic drug-metabolizing enzyme induction and implications for preclinical and clinical risk assessment.
    Mohutsky MA; Romeike A; Meador V; Lee WM; Fowler J; Francke-Carroll S
    Toxicol Pathol; 2010 Aug; 38(5):799-809. PubMed ID: 20616377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug.
    Zhang H; Cui D; Wang B; Han YH; Balimane P; Yang Z; Sinz M; Rodrigues AD
    Clin Pharmacokinet; 2007; 46(2):133-57. PubMed ID: 17253885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition and induction of cytochrome P450 and the clinical implications.
    Lin JH; Lu AY
    Clin Pharmacokinet; 1998 Nov; 35(5):361-90. PubMed ID: 9839089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advantages of cell-based high-volume screening assays to assess nuclear receptor activation during drug discovery.
    Pinne M; Raucy JL
    Expert Opin Drug Discov; 2014 Jun; 9(6):669-86. PubMed ID: 24819724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Key Findings from Preclinical and Clinical Drug Interaction Studies Presented in New Drug and Biological License Applications Approved by the Food and Drug Administration in 2014.
    Yu J; Ritchie TK; Zhou Z; Ragueneau-Majlessi I
    Drug Metab Dispos; 2016 Jan; 44(1):83-101. PubMed ID: 26424199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design and Implementation of High-Throughput Screening Assays.
    Powell DJ; Hertzberg RP; Macarrόn R
    Methods Mol Biol; 2016; 1439():1-32. PubMed ID: 27316985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin.
    Li AP; Reith MK; Rasmussen A; Gorski JC; Hall SD; Xu L; Kaminski DL; Cheng LK
    Chem Biol Interact; 1997 Nov; 107(1-2):17-30. PubMed ID: 9402947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Using high-content screening technology for studying drug-induced hepatotoxicity in preclinical studies.
    Donato MT; Gómez-Lechón MJ; Tolosa L
    Expert Opin Drug Discov; 2017 Feb; 12(2):201-211. PubMed ID: 27936962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of CYP-mediated drug interactions in vivo using in vitro data.
    Foti RS; Wahlstrom JL
    IDrugs; 2008 Dec; 11(12):900-5. PubMed ID: 19051152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of drug metabolising enzymes: pharmacokinetic and toxicological consequences in humans.
    Fuhr U
    Clin Pharmacokinet; 2000 Jun; 38(6):493-504. PubMed ID: 10885586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Introduction to hepatic drug metabolizing enzyme induction in drug safety evaluation studies.
    Botts S; Ennulat D; Francke-Carroll S; Graham M; Maronpot RR; Mohutsky M
    Toxicol Pathol; 2010 Aug; 38(5):796-8. PubMed ID: 20622194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Rapid pharmacokinetics screening of drug candidates in vitro and in vivo].
    Dong XN; Zhu XX; Meng ZY; Liu JL; Cao YL; Dou GF
    Yao Xue Xue Bao; 2009 Nov; 44(11):1309-12. PubMed ID: 21355332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of drug-metabolizing enzymes: mechanisms and consequences.
    Okey AB; Roberts EA; Harper PA; Denison MS
    Clin Biochem; 1986 Apr; 19(2):132-41. PubMed ID: 3518989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application of cytochrome P450 drug interaction screening in drug discovery.
    Foti RS; Wienkers LC; Wahlstrom JL
    Comb Chem High Throughput Screen; 2010 Feb; 13(2):145-58. PubMed ID: 20053168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-Throughput Cell Toxicity Assays.
    Murray D; McWilliams L; Wigglesworth M
    Methods Mol Biol; 2016; 1439():245-62. PubMed ID: 27317000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-throughput assay development for combined in vitro toxicity screening of hit compounds and their metabolites in early drug-discovery stage.
    Siricilla S
    Bioanalysis; 2017 Jul; 9(13):959-961. PubMed ID: 28708435
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.